CXCR5 and non-small cell lung carcinoma: The possibility to target EGFR expressed by NSCLC cells has been also investigated by the use of anti-EGFR CAR T, further modified to express C-X-C Chemokine receptor type 5 (CXCR5), in a phase I clinical study (NCT04153799).